BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 25894430)

  • 1. Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study.
    Ohta K; Ichinose M; Tohda Y; Engel M; Moroni-Zentgraf P; Kunimitsu S; Sakamoto W; Adachi M
    PLoS One; 2015; 10(4):e0124109. PubMed ID: 25894430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis.
    Dahl R; Engel M; Dusser D; Halpin D; Kerstjens HAM; Zaremba-Pechmann L; Moroni-Zentgraf P; Busse WW; Bateman ED
    Respir Med; 2016 Sep; 118():102-111. PubMed ID: 27578478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids.
    Vogelberg C; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Hamelmann E; Engel M; Szefler S
    Respir Res; 2015 Feb; 16(1):20. PubMed ID: 25851298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma.
    Timmer W; Moroni-Zentgraf P; Cornelissen P; Unseld A; Pizzichini E; Buhl R
    Respir Med; 2015 Mar; 109(3):329-38. PubMed ID: 25661281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial.
    Paggiaro P; Halpin DM; Buhl R; Engel M; Zubek VB; Blahova Z; Moroni-Zentgraf P; Pizzichini E
    J Allergy Clin Immunol Pract; 2016; 4(1):104-13.e2. PubMed ID: 26563670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tiotropium in asthmatic adolescents symptomatic despite inhaled corticosteroids: a randomised dose-ranging study.
    Vogelberg C; Engel M; Moroni-Zentgraf P; Leonaviciute-Klimantaviciene M; Sigmund R; Downie J; Nething K; Vevere V; Vandewalker M
    Respir Med; 2014 Sep; 108(9):1268-76. PubMed ID: 25081651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma.
    Beeh KM; Moroni-Zentgraf P; Ablinger O; Hollaenderova Z; Unseld A; Engel M; Korn S
    Respir Res; 2014 Jun; 15(1):61. PubMed ID: 24890738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials.
    Kerstjens HA; Casale TB; Bleecker ER; Meltzer EO; Pizzichini E; Schmidt O; Engel M; Bour L; Verkleij CB; Moroni-Zentgraf P; Bateman ED
    Lancet Respir Med; 2015 May; 3(5):367-76. PubMed ID: 25682232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status.
    Kerstjens HA; Moroni-Zentgraf P; Tashkin DP; Dahl R; Paggiaro P; Vandewalker M; Schmidt H; Engel M; Bateman ED
    Respir Med; 2016 Aug; 117():198-206. PubMed ID: 27492532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma.
    Kew KM; Dahri K
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD011721. PubMed ID: 26798035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.
    Kew KM; Evans DJ; Allison DE; Boyter AC
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD011438. PubMed ID: 26031392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
    Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
    Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma.
    Szefler SJ; Murphy K; Harper T; Boner A; Laki I; Engel M; El Azzi G; Moroni-Zentgraf P; Finnigan H; Hamelmann E
    J Allergy Clin Immunol; 2017 Nov; 140(5):1277-1287. PubMed ID: 28189771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tiotropium add-on therapy in adolescents with moderate asthma: A 1-year randomized controlled trial.
    Hamelmann E; Bateman ED; Vogelberg C; Szefler SJ; Vandewalker M; Moroni-Zentgraf P; Avis M; Unseld A; Engel M; Boner AL
    J Allergy Clin Immunol; 2016 Aug; 138(2):441-450.e8. PubMed ID: 26960245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The efficacy and safety of combined tiotropium and olodaterol via the Respimat(®) inhaler in patients with COPD: results from the Japanese sub-population of the Tonado(®) studies.
    Ichinose M; Taniguchi H; Takizawa A; Grönke L; Loaiza L; Voß F; Zhao Y; Fukuchi Y
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2017-27. PubMed ID: 27621608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.
    Hamelmann E; Bernstein JA; Vandewalker M; Moroni-Zentgraf P; Verri D; Unseld A; Engel M; Boner AL
    Eur Respir J; 2017 Jan; 49(1):. PubMed ID: 27811070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tiotropium Respimat®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting β2-Adrenergic Agonists.
    McKeage K
    Drugs; 2015 May; 75(7):809-16. PubMed ID: 25895466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
    ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
    Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life.
    Singh D; Ferguson GT; Bolitschek J; Grönke L; Hallmann C; Bennett N; Abrahams R; Schmidt O; Bjermer L
    Respir Med; 2015 Oct; 109(10):1312-9. PubMed ID: 26320402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tiotropium for the treatment of asthma in adolescents.
    Hamelmann E; Vogelberg C; Szefler SJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):305-312. PubMed ID: 28110558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.